Stockscreener 앱 받기
25.85
1.93%
-0.51
전일 마감가:
$26.36
열려 있는:
$26.49
하루 거래량:
1.09M
Relative Volume:
0.50
시가총액:
$3.17B
수익:
$59.61M
순이익/손실:
$-262.14M
주가수익비율:
-6.5944
EPS:
-3.92
순현금흐름:
$-247.49M
1주 성능:
-8.40%
1개월 성능:
-9.39%
6개월 성능:
+67.53%
1년 성능:
+88.00%
1일 변동 폭
$25.80
$26.62
1주일 범위
$25.35
$28.10
52주 변동 폭
$11.13
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
명칭
Arcutis Biotherapeutics Inc
전화
805-418-5006
주소
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
ARQT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
25.85 | 3.23B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 개시 | Goldman | Neutral |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-28 | 개시 | Jefferies | Buy |
| 2024-01-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-26 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-10-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-09-07 | 개시 | Needham | Buy |
| 2022-03-17 | 개시 | Goldman | Buy |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-05-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-10-08 | 개시 | Truist | Buy |
| 2020-02-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-02-25 | 개시 | Cowen | Outperform |
| 2020-02-25 | 개시 | Goldman | Neutral |
| 2020-02-25 | 개시 | Guggenheim | Buy |
모두보기
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Published on: 2026-01-17 08:06:24 - baoquankhu1.vn
Is Arcutis Biotherapeutics Inc stock undervalued right nowMarket Weekly Review & Weekly Top Gainers Trade List - baoquankhu1.vn
Price-Driven Insight from (ARQT) for Rule-Based Strategy - Stock Traders Daily
Market Moves: Is Arcutis Biotherapeutics Inc stock good for income investorsPortfolio Update Report & Community Driven Trade Alerts - baoquankhu1.vn
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Unloaded Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT): Investor Outlook Reveals 18% Upside Potential - DirectorsTalk Interviews
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 7.3%Here's What Happened - MarketBeat
Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus - TechStock²
Arcutis highlights 2026 strategic priorities and anticipated milestones - marketscreener.com
Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones - The Manila Times
Skin drug maker maps 2026 plans, from infant trials to $470M sales - Stock Titan
Risk Recap: Is Arcutis Biotherapeutics Inc. stock a buy before product launchesMarket Movers & Fast Gaining Stock Reports - ulpravda.ru
Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings - TechStock²
Earnings Report: Will Arcutis Biotherapeutics Inc. stock beat EPS estimatesJuly 2025 Rallies & Reliable Entry Point Trade Alerts - Улправда
How Arcutis Biotherapeutics Inc. stock compares to growth peersEarnings Overview Summary & Weekly Chart Analysis and Guides - ulpravda.ru
Is Arcutis Biotherapeutics Inc. stock a buy before product launchesMarket Movers & Fast Gaining Stock Reports - ulpravda.ru
Patrick Burnett Sells 2,490 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Arcutis Bio EVP Burnett sells $72k in shares By Investing.com - Investing.com Canada
Arcutis Bio EVP Burnett sells $72k in shares - Investing.com
Arcutis Biotherapeutics, Inc.Common stock (NQ: ARQT - FinancialContent
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: Revenue Surge and Analyst Consensus Signal Opportunity - DirectorsTalk Interviews
Arcutis BiotherapeuticsFocusing On ZORYVE Market Expansion And Pipeline Growth - RTTNews
Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
(ARQT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Arcutis Biotherapeutics CEO Todd Watanabe sells $245,122 in shares - MSN
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $49,552.40 in Stock - MarketBeat
Arcutis Biotherapeutics EVP Burnett sells $49,560 in shares By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics EVP Burnett sells $49,560 in shares - Investing.com
Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates - TechStock²
Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day - ts2.tech
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 3.4%Still a Buy? - MarketBeat
Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade - ts2.tech
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Rating Lowered by Zacks Research - MarketBeat
Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3% - ts2.tech
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: A 10.73% Potential Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews
Arcutis Biotherapeutics, Inc. $ARQT Shares Sold by Simplify Asset Management Inc. - MarketBeat
Arcutis Biotherapeutics Earnings Notes - Trefis
Arcutis Biotherapeutics (NASDAQ:ARQT) Downgraded by Wall Street Zen to Buy - MarketBeat
Is Suvretta’s Stake Cut and FDA’s Pediatric Review Acceptance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)? - Yahoo Finance
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - Yahoo Finance
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - The Motley Fool
How Low Can Arcutis Biotherapeutics Stock Really Go? - Trefis
Why Arcutis Biotherapeutics Inc. stock remains resilientRate Cut & Weekly Watchlist of Top Performers - Улправда
Perpetual Ltd Increases Stake in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Will Arcutis Biotherapeutics Inc. stock gain from strong economyJuly 2025 Pullbacks & Technical Pattern Alert System - Улправда
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? - Yahoo Finance Australia
Is Arcutis Biotherapeutics Inc. stock attractive for growth ETFsJuly 2025 EndofMonth & Momentum Based Trading Ideas - DonanımHaber
Arcutis Biotherapeutics Inc (ARQT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):